All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Sequence of therapy in myelodysplastic syndromes

The MDS Hub was pleased to speak to Moshe Mittelman, Tel Aviv University, Tel Aviv, IL. We asked, What is the sequence of therapy in myelodysplastic syndromes (MDS)?

Sequence of therapy in myelodysplastic syndromes

Mittelman begins by explaining how the sequence of therapy is dependant on the individual patient's risk classification. Mittelman goes on to discuss response rates for different drugs including lenalidomide and erythroid-stimulating agents. Finally, Mittelman discusses drugs currently under investigation, and using stem cell transplant (SCT) as a possible approach in the future.